Anti-CD19 Anti-CD22 CAR-T cell therapy(PersonGen BioTherapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 Anti-CD22 CAR-T cell therapy(PersonGen BioTherapeutics)

Drug Alias NameCD19/CD22-CAR-T

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPersongen Biotherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A